Agentix Corp. reported its financial results for the three months ended June 30, 2026, revealing a net loss of $117,674, a decrease from a net loss of $185,824 during the same period in 2025. The company did not generate any revenue in either quarter. Total operating expenses for the latest quarter were $95,504, significantly lower than the $200,342 reported in the prior year, primarily due to reduced professional fees and research and development costs. Professional fees decreased to $62,084 from $82,625, while research and development expenses fell sharply to $16,635 from $100,000.

In terms of financial position, Agentix Corp. reported total current liabilities of $3,713,831 as of June 30, 2026, up from $3,596,282 at the end of the previous fiscal period. The company’s accumulated deficit increased to $7,124,838, compared to $7,007,164 as of March 31, 2026. Cash reserves dwindled to $38, down from $771, raising concerns about the company's ability to continue operations without additional funding. The company has indicated that it will need to secure further financing to support its operational expenses and business plan.

Agentix Corp. has not made any significant acquisitions or product launches during the reported period. The company continues to focus on developing therapeutic agents for metabolic diseases, including Type 2 diabetes and obesity. As of June 30, 2026, the company maintained a consistent employee headcount of 40, with no new hires or layoffs reported. The company’s operational strategy remains centered on reducing costs and managing liabilities while seeking opportunities for revenue generation.

Looking ahead, Agentix Corp. faces substantial challenges, particularly regarding its liquidity and ability to raise funds. The company has acknowledged that its current cash position is insufficient to support daily operations, and it will likely pursue equity or debt financing to meet its financial needs. However, management has cautioned that there are no guarantees of successful fundraising, which could jeopardize the company's future operations. The outlook remains uncertain as the company navigates these financial hurdles while attempting to implement its business strategy.

About Agentix Corp.

Agentix Corp. is a clinical-stage biotechnology company focused on developing novel therapeutics for metabolic diseases, including type 2 diabetes, obesity, and non-alcoholic fatty liver disease. Its pipeline features peripherally-restricted cannabinoid receptor 1 antagonists designed to avoid central nervous system side effects. Agentix aims to advance early clinical development and partner with larger biopharma firms for commercialization, targeting a global market affected by metabolic syndrome.

This description was generated via AI from an annual report. Updated about 1 year ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.

View the complete official filing on the SEC website.

Read on SEC.gov